Monoclonal Antibody Avelumab in Non-Resectable Advanced Merkel Cell Carcinoma: Review of Literature

Introduction: Merkel cell carcinoma (MCC) is an aggressive form of skin cancer typically associated with a poor prognostic outcome. Case description: A case of non-resectable, advanced Merkel cell carcinoma of the right pelvis and right inguinal region in a 67-year-old man was treated with the anti PD-L1 monoclonal antibody avelumab and Radiation therapy, with maintenance of a durable response 24 months later. The rare presentation of this aggressive form of skin cancer and its clinicopathologic features are presented. Conclusions: Up-to-date information on the clinical management of MCC, including the utilization of human anti-PD-L1 monoclonal antibody, and ongoing clinical trials in both localized and metastatic settings of MCC are discussed.